Results 11 to 20 of about 4,289 (137)

Glycosylated fibronectin improves first‐trimester prediction of pre‐eclampsia

open access: yesUltrasound in Obstetrics &Gynecology, Volume 62, Issue 4, Page 512-521, October 2023., 2023
ABSTRACT Objective To determine whether maternal serum glycosylated fibronectin (GlyFn) level in the first trimester increases the sensitivity of the Fetal Medicine Foundation (FMF) triple test, which incorporates mean arterial pressure, uterine artery pulsatility index and placental growth factor, when screening for pre‐eclampsia (PE) in an Asian ...
S. Moungmaithong   +7 more
wiley   +1 more source

孕中期高危孕妇外周血中胎儿游离DNA与高危产前诊断指征相关性分析

open access: yesZhongguo shiyan zhenduanxue, 2021
目的分析孕中期高危孕妇外周血中胎儿游离DNA(Cell-free fetal DNA,cffDNA)与高危产前诊断指征相关性。方法研究对象为2018年7月-2019年7月在遂宁市中心医院产前诊断中心接受外周血cffDNA筛查的3176例孕中期高危孕妇,记录高危产前诊断指征、cffDNA检测结果,分析不同高危产前诊断指征的孕中期高危孕妇外周血cffDNA筛查结果,以染色体核型检查结果为对照,分析孕中期高危孕妇外周血中cffDNA的筛查价值。结果3176例孕中期高危孕妇的产前诊断指征分别为高龄(年龄≥35岁)
赵咏梅, 张传英, 席海林
doaj  

性染色体数目异常疾病诊断技术研究进展 [PDF]

open access: yes, 2018
性染色体数目异常疾病是一类严重困扰人类生活的综合征,患者多能生存,但常有性腺发育不全、多发畸形、不育等异常表现。该病无法治愈,经激素替代治疗等干预措施可有效缓解症状,但早期确诊严重依赖于相关临床诊断技术的发展。该文拟就现今常见检测性染色体数目异常技术的发展作一综述,比较各技术优缺点及评价其在临床诊断中的应用价值,以方便检验工作者科学合理地采用相关技术,为临床提供更为准确可靠的实验室依据,推进对该类疾病的诊治与研究。国家自然科学基金面上项目(81572084);;厦门市科技重大专项 ...
周裕林, 郑欣怡
core   +1 more source

3种B族链球菌筛查方法在孕晚期筛查中的应用 [PDF]

open access: yes, 2019
目的比较3种B族链球菌(GBS)的筛查方法在孕晚期孕妇GBS筛查中的临床应用价值。方法收集2017年9月至12月在厦门市妇幼保健院产科门诊产检的35~37孕周孕妇阴道/直肠拭子样本1 027例,用GBS运送增菌...厦门市第二批青年创新创业人才项目(2015-A ...
叶辉铭   +4 more
core   +1 more source

在出生后第一年接受手术的患有肾积水的儿童接受治疗的长期结果。系统综述

open access: yes, 2023
BACKGROUND: Congenital stenosis of the ureterоpelvic junction is the most common cause of hydronephrosis in children. AIM: This systematic review aimed to search and analyze modern literature from 1998 to 2021 on the treatment and postoperative follow-up
Agavelyan A.E.   +5 more
core   +1 more source

秦皇岛地区20000例孕妇无创DNA产前检测结果分布及因素分析

open access: yesZhongguo shiyan zhenduanxue, 2021
检测及生物信息分析对孕妇外周血浆中母体、胚胎游离DNA片段进行测序计算,分析胎儿染色体是否存在非整倍体变异现象[1-2]。出生缺陷是重要的人类健康问题,包括唐氏综合征、先天性心脏病、神经管缺陷,因此产前筛查、诊断是关键环节。影像学、血清生化学等检查被广泛应用于临床筛查,然而侵入性产检、假阳性率较高等问题可能对孕妇造成一定伤害性风险和心理性问题[3-4]。2011年NIPT技术开始在临床中推广,该方法在孕周达到10周以上时即可采血进行,不仅提前了诊断时间,而且容易被孕妇接受[5]。在我国每年有约90 ...
张丽红   +5 more
doaj  

Detection of Aneuploidy Using Suspension Array Technology after Multiplex Ligation-dependent Probe Amplification [PDF]

open access: yes, 2009
摘要 本论文围绕作为新一代分子诊断技术平台的液相芯片检测平台展开,以染色体非整倍体异常疾病为对象,首次提出结合多重连接探针扩增(MLPA)的液相悬浮芯片技术(又称MLPA-液相悬浮芯片技术),并且考察该技术在定量分析方面的应用潜力。染色体非整倍体异常疾病是一类因染色体数目增加或减少引起的发病率高的遗传性疾病,是孕妇需要进行产前检查的主要原因之一。因此将染色体非整倍体异常疾病作为检测对象探讨该技术检测拷贝数异常的可行性,既有技术创新性又有实际检测意义。 第一章 ...
曾懿
core  

Cost–benefit analysis of first‐trimester pre‐eclampsia screening: comparison of multivariable Gaussian algorithm with and without placental growth factor

open access: yesUltrasound in Obstetrics &Gynecology, Volume 67, Issue 2, Page 162-167, February 2026.
ABSTRACT Objective Pre‐eclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Early identification of high‐risk pregnancies in the first trimester allows preventive treatment with low‐dose aspirin. This study aimed to evaluate whether multivariable Gaussian algorithm‐based PE screening strategies, with and without
E. Bonacina   +10 more
wiley   +1 more source

AFP、β-hCG和uE3联合检测在孕中期产前出生缺陷筛查中的应用价值

open access: yesZhongguo shiyan zhenduanxue, 2020
目的探讨孕中期血清甲胎蛋白(AFP)、绒毛膜促性腺激素β亚单位(β-HCG)、非结合型雌三醇(uE3)联合检测在孕中期产前出生缺陷筛查中的应用价值。方法选取2015年1月—2017年4月在我院产科门诊建卡、行常规产检并分娩的妊娠妇女3617例为研究对象,以羊水细胞染色体检查、随访分娩结局作为判断出生缺陷金标准,评价血清AFP、β-HCG、uE3三联指标在产前筛查中的临床应用价值。结果血清AFP、β-HCG和uE3联合检测发现高风险孕妇138例,其中21三体综合征高风险126例(91.30 ...
高春利, 薛晓丽, 窦娟
doaj  

Performance of non‐invasive prenatal testing in vanishing‐twin and multiple pregnancies: results of TRIDENT‐2 study

open access: yesUltrasound in Obstetrics &Gynecology, Volume 66, Issue 6, Page 738-746, December 2025.
ABSTRACT Objective To evaluate the performance of non‐invasive prenatal testing (NIPT) in vanishing‐twin and multiple pregnancies. Methods This study was conducted as part of the TRIDENT‐2 study, in which NIPT was offered as a first‐tier screening test to women with a multiple pregnancy or vanishing‐twin pregnancy between 1 June 2020 and 31 March 2023 ...
J. C. A. van Eekhout   +86 more
wiley   +1 more source

Home - About - Disclaimer - Privacy